A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with advanced-stage disease is needed.
A new study led by Yale Cancer Center researchers at Yale School of Medicine revealed a significant increase in patients starting immunotherapy within one month
Metastatic cancer patients more likely to survive at academic and high-volume hospitals when given immunotherapy: Study medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased
Mario Sznol, MD, is a professor of medicine, vice-chief of the Section of Medical Oncology, co-director of the Yale SPORE in Skin Cancer, and leader of the Translational Research Program, Melanoma, at Yale Cancer Center in New Haven, Connecticut.